Failure of alemtuzumab therapy in three patients with MOG antibody associated disease
Sign Up to like & getrecommendations! Published in 2022 at "BMC Neurology"
DOI: 10.1186/s12883-022-02612-6
Abstract: Background Myelin Oligodendrocyte Glycoprotein antibody-associated disease (MOGAD) is most classically associated in both children and adults with phenotypes including bilateral and recurrent optic neuritis (ON) and transverse myelitis (TM), with the absence of brain lesions… read more here.
Keywords: failure alemtuzumab; antibody; antibody associated; associated disease ... See more keywords
Failure of alemtuzumab therapy to control MOG encephalomyelitis
Sign Up to like & getrecommendations! Published in 2017 at "Neurology"
DOI: 10.1212/wnl.0000000000004087
Abstract: Myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G (IgG)–associated encephalomyelitis (EM) is a rare autoimmune disorder that displays substantial clinicoradiologic overlap with aquaporin-4 (AQP4)-IgG-seropositive neuromyelitis optica spectrum disorders (NMOSD) and classic multiple sclerosis (MS).1–3,e1 The long-term outcome… read more here.
Keywords: igg; failure alemtuzumab; encephalomyelitis; therapy control ... See more keywords